News and Press

Ventria’s success in excluding unfairly traded imports secures its ability to continue to invest in the next generation of plant biotechnology innovation  Junction City, Kansas – September 14th, 2022 – Ventria Bioscience Inc. (Ventria) today announced that the United States International Trade Commission (ITC) completed its review of Administrative Law Judge McNamara’s previous determination and affirmed the […]

Ventria Bioscience Inc. today announced it has completed the doubling of its capacity for cell culture products and is breaking ground on an additional expansion of its footprint to further enhance Ventria’s capacity for production of cell culture products, including recombinant proteins.

New Business Unit Announcement Ventria Bioscience announces the launch of its new business unit, CuraVive. The new subsidiary is solely focused on leading the innovation in plant-based functional food ingredients. CuraVive applies over 20 years of Ventria Bioscience’s plant protein production experience to create high-performance plant-based food ingredients of unmatched quality and safety. CuraVive is […]

For immediate release – Junction City, KS  Last week, Ventria Bioscience Inc. obtained an important win in its effort to stop the importation and sale of infringing recombinant albumin made in China by Wuhan Healthgen Biotechnology Corp. On August 18, 2021, the U.S. International Trade Commission (ITC) formally found three U.S. distributors of such products—Aspira […]

  The ongoing COVID-19 pandemic has become a major source of disruption and upheaval to normal daily routines. The repeated opening and re-shuttering of schools and universities in response to spiking case numbers, for example, highlights the need for preventative treatments before a return to normalcy is possible. While vaccines are being developed, other prevention […]

As of the date of this writing, there have been more than 8 million confirmed cases of COVID-19 worldwide, and close to half a million deaths. The pandemic’s initial, exponential growth trajectory has been contained through massive voluntary and mandatory isolation efforts; however, these have had their own disastrous consequences for the economy and for […]

Junction City, Kansas – November 21, 2019 – A recent publication, Human Milk Proteins: Their Power to Improve the Health Status of Children in Developing Countries, explores the critical health benefits of synthetic human breastmilk proteins for children in developing countries. In poverty-stricken areas, children are more likely to suffer from Environmental Enteric Dysfunction (EED) […]

It has long been known that human breastmilk provides crucial health advantages to newborn infants as they develop, and has been a topic of intense research. Current clinical innovations seek to harness the benefits of human breastmilk to address global medical needs. With functions such as energy provision, immunologic power, and gut maturation, there are […]

Effects of rhLactoferrin on Chronic Inflammation in the Elderly: Design and Objectives of the ELCIE Clinical Trial We have previously introduced an ongoing clinical study, headed by principal investigator Jeremy Walston, MD,  Johns Hopkins School of Medicine, aimed at finding out if recombinant human lactoferrin (rhLactoferrin) produced from Ventria Bioscience’s ExpressTec biologic manufacturing system may […]

In a previous post, we discussed how the composition of human breastmilk protects infant health and aids in the early development of the gut and immune system. We also talked about how some of those beneficial properties can be isolated to specific milk proteins that can now be produced affordably, in high yield, for clinical […]